Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors.
Aged
Aged, 80 and over
Cochlear Diseases
/ diagnosis
Female
Hearing Tests
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Male
Melanoma
/ complications
Middle Aged
Molecular Targeted Therapy
/ adverse effects
Ototoxicity
/ diagnosis
Symptom Assessment
Tomography, X-Ray Computed
Vestibular Diseases
/ diagnosis
Journal
Journal of immunotherapy (Hagerstown, Md. : 1997)
ISSN: 1537-4513
Titre abrégé: J Immunother
Pays: United States
ID NLM: 9706083
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
04
06
2020
accepted:
02
02
2021
pubmed:
19
3
2021
medline:
18
1
2022
entrez:
18
3
2021
Statut:
ppublish
Résumé
Immune-related adverse events have been described in 86%-96% of high-risk melanoma patients treated with immune checkpoint inhibitors (ICI), while in 17%-59% of cases these are classified as severe or even life-threatening. The most common immune-related adverse events include diarrhea, fatigue, hypothyroidism, and hepatitis. Bilateral uveitis and unspecific vertigo have been described in 1% of cases, respectively, in the pivotal studies of ICIs, but the affection of the vestibule-cochlear system has not been reported before. In this case series, we present 3-stage IV melanoma patients with sudden onset of otovestibular dysfunction (hearing loss and vestibulopathy), partly combined with uveitis because of ICIs. We describe detailed diagnostic work-up and therapeutic interventions and discuss possible pathogenic mechanisms of this rare and disabling event.
Identifiants
pubmed: 33734141
doi: 10.1097/CJI.0000000000000367
pii: 00002371-202106000-00003
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-197Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Larkin J, Chiarion-Sileni V, Gonzalez R. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–1546.
Wolchok JD, Chiarion-Sileni V, Gonzalez R. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356.
Schachter J, Ribas A, Long GV. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–1862.
Long GV, Atkinson V, Cebon JS. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18:1202–1210.
Heinzerling L, de Toni E, Schett G. Checkpoint inhibitors. Dtsch Arztebl Int. 2019;116:119–126.
LaFerriere KA, Arenber IK, Hawkins JE, et al. Melanocytes of the vestibular labyrinth and their relationship to the microvasculature. Ann Otol Rhinol Laryngol. 1974;83:685–694.
Strupp M. Bilateral vestibulopathy: diagnostic criteria consensus document of the Classification Committee of the Bárány Society. Adv Ther. 2017:177–189.
Robert C, Schachter J, Long GV. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
Hartl DM, Morel D, Saavedra E. Otorhinolaryngological toxicities of new drugs in oncology. Adv Ther. 2017;34:866–894.
Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016;4:8.
Johnson LA, Morgan RA, Dudley ME. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535–546.
Zhang F, Zhang J, Neng L. Characterization and inflammatory response of perivascular resident macrophage-like melanocytes in the vestibular system. JARO. 2013;14:635–643.